Application of complement component 4d immunohistochemistry to ABO‐compatible and ABO‐incompatible liver transplantation

Adeeb Salah, Masakazu Fujimoto, Atsushi Yoshizawa, Kimiko Yurugi, Aya Miyagawa‐Hayashino, Shinji Sumiyoshi, Sachiko Minamiguchi, Shinji Uemoto, Taira Maekawa, Hironori Haga – 6 November 2013 – Antibody‐mediated rejection (AMR) is difficult to diagnose after ABO‐compatible or ABO‐identical (ABO‐C) liver transplantation. To determine whether complement component 4d (C4d) immunostaining would be useful for diagnosing AMR, we compared the results of C4d immunohistochemistry for allograft biopsy samples with assays for anti‐donor antibodies performed at the time of biopsy.

Antibody‐mediated rejection as a contributor to previously unexplained early liver allograft loss

Jacqueline G. O'Leary, Hugo Kaneku, Anthony J. Demetris, John D. Marr, S. Michelle Shiller, Brian M. Susskind, Glenn W. Tillery, Paul I. Terasaki, Göran B. Klintmalm – 6 November 2013 – We analyzed 60 patients with idiopathic early allograft loss (defined as death or retransplantation at <90 days) to determine the relative contribution of preformed donor‐specific human leukocyte antigen alloantibodies (DSAs) to this endpoint, and we defined strict criteria for the diagnosis of antibody‐mediated rejection (AMR) in liver allografts.

Subscribe to